Biocept Inc., a liquid biopsy test maker in San Diego, has appointed David Moskowitz to the newly created role of vice president of strategy and corporate communications.
Moskowitz will execute Biocept’s corporate strategy and coordinate the company’s investor relations and public relations activities.
Moskowitz comes from Trovagene Inc., where he worked as vice president of investor relations. Earlier in his career, Moskowitze worked on Wall Street as director of equity research at Caris & Co. and head of health care research at Friedman Billings Ramsey. He also did strategic advisory work and capital markets planning for biopharmaceutical and molecular diagnostics companies, according to a Biocept news release.
“We are committed to building on our leadership position in the emerging liquid biopsy field and bringing value to our shareholders,” Michael Nall, president and CEO of Biocept, said in a statement. “David’s direct sector experience and 16 years at leading Wall Street firms make him ideally suited to support these corporate goals. David will play an instrumental role in formulating and implementing strategies aimed at our success and will use his proven skills to effectively communicate our progress.”
Biocept is a small public company in San Diego with a current market cap of about $16.8 million. The company, which is developing liquid biopsy tests for cancer, has watched its stock fall 85 percent in the past 12 months.
